meningococcal groups a, b, c, w, and Y vaccine
Trade name: PENBRAYA
Vaccineapproved
Approved
Oct 20, 2023
Clinical trial activity
10 trials · 5 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
3
Phase 4
1
Earliest trial started Jun 19, 2020 (NCT04440176)
Timeline
Indications
Approved for
Mechanism of action
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
Approval history
- approvedOct 20, 2023
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07197762 | Phase 4 | Oct 31, 2025 | Emory University, Pfizer |
| NCT06647407 | Phase 1/Phase 2 (Phase 2) | Oct 28, 2024 | Sanofi-Aventis |
| NCT06128733 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Sanofi, Sanofi-Aventis |
| NCT05082285 | Phase 2 | Nov 29, 2021 | GlaxoSmithKline |
| NCT04886154 | Phase 1/Phase 2 (Phase 2) | Jun 14, 2021 | GlaxoSmithKline |
| NCT04707391 | Phase 3 | Jan 25, 2021 | GlaxoSmithKline |
| NCT04645966 | Phase 2 | Nov 24, 2020 | Pfizer |
| NCT04502693 | Phase 3 | Aug 14, 2020 | GlaxoSmithKline |
| NCT04440163 | Phase 3 | Jun 19, 2020 | Pfizer |
| NCT04440176 | Phase 2 | Jun 19, 2020 | Pfizer |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2020 |
| Pfizer | For profit | 4 | 3 | 3 | 2020 |
| Sanofi-Aventis | For profit | 2 | 2 | 1 | 2023 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Sanofi | For profit | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Pfizer | For profit | NDA | Oct 20, 2023 |